| Literature DB >> 35692732 |
Elizabeth A Bullard1, Ariel I Mundo1, Shelby N Bess1, Kathryn Miller Priest1, Timothy J Muldoon1.
Abstract
Ulcerative colitis (UC) is a gastrointestinal, autoimmune disease that causes ulceration and inflammation of the colon with an incidence of 10 out of every 100,000 people in North America and Western Europe. Though the specific cause is unknown, several studies have demonstrated that inflammatory cells as well as environmental variables, genetics, and lifestyle behaviors can play a role in the long-term inflammatory response. Researchers have commonly used immunohistochemistry, western blotting and gene sequencing to establish the cellular processes behind UC relapse and remission. However, because these destructive methods necessitate the removal of a sample, they can only be used on non-living tissues. The use of minimally invasive approaches to evaluate the in vivo, longitudinal effects of UC on the mucosa in the colon is gaining popularity among clinicians and researchers. We have created a dextran sulfate sodium-induced model of UC in C57 mice based on the work of Wirtz et al., and a minimally invasive imaging modality to explore the changes in mucosal tissue during "active" and "in remission" UC. Briefly, C57 mice were given dextran sulfate sodium (DSS) dissolved in water in 5-day cycles with a remission/recovery period of 10 days. After 7 days post-DSS treatment and 7 days post-recovery, mice were anesthetized and exploratory endoscopies were performed to assess the mucosal changes that occur during the "active" and "remission" periods of UC. Value of protocol:•Minimally invasive induction of ulcerative colitis in a murine mouse model.•Minimally invasive longitudinal monitoring of "active" and "in remission" ulcerative colitis.•Our endoscopic based imaging modality can be used to validate the induction of ulcerative colitis and the potential treatment response for pre-clinical trials.Entities:
Keywords: Dextran sulfate sodium; Endoscopy; Ulcerative colitis
Year: 2022 PMID: 35692732 PMCID: PMC9178474 DOI: 10.1016/j.mex.2022.101744
Source DB: PubMed Journal: MethodsX ISSN: 2215-0161
Fig. 2Sample Timeline of DSS administration with colonoscopies. Control mice are scoped every week without any DSS. DSS treated mice receive 5 days of 4% DSS with a 10-day recovery period between each cycle. This simulates the “active” and “remission” cycling of UC. DSS was administered for 12 weeks and the final colonoscopy and euthanasia occurred on day 76.
Fig. 3(A) Normal colon mucosa. (B) DSS-induced ulcer in the mucosa. (C) Optical probe making contact with an ulcer 76 days post-DSS treatment. (D) Longitudinal weight changes from C57BL/6J control (n = 5) and DSS induced mice (n = 9). Raw weight plots were made in GraphPad Prism©. (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.0001, Mann-Whitney test).
Descriptions of the Mayo Endoscopic Subscoring system.
| Mayo Endoscopic Subscore | Description |
|---|---|
| 0 | Normal mucosa or inactive disease |
| 1 | Mild activity (erythema, decreased vascular pattern, mild friability |
| 2 | Moderate activity (marked erythema, lack of vascular pattern, friability, erosions) |
| 3 | Severe activity (spontaneous bleeding, large ulcerations) |
| Engineering | |